Athersys, Inc. (NASDAQ:ATHX) saw a big move last session, as the company’s shares fell by over 51% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for ATHX, as the stock is now down around 61% since April 1. Athersys, Inc. (NASDAQ:ATHX) shares after opening at $1.28 moved to $1.51 on last trade day and at the end of the day closed at $1.43 . Company price to sales ratio in past twelve months was calculated as 45.94 and price to cash ratio as 3.46. Athersys, Inc. (NASDAQ:ATHX) showed a negative weekly performance of -51.36%.
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) announced that it will report its first quarter 2014 financial results on Thursday, May 8, 2014 at approximately 8:00 a.m. ET. The press release will be followed by a conference call and webcast at 8:30 a.m. ET. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) shares advanced 6.86% in last trading session and ended the day on $26.80. NPSP return on equity ratio is recorded as -19.50% and its return on assets is -5.20%. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) yearly performance is 95.76%.
Cytokinetics Inc. (NASDAQ:CYTK) has just released additional data from the Phase IIb BENEFIT-ALS of tirasemtiv. These data confirm the worst case scenario for the drug, in our view. The trial not only failed to meet the primary endpoint of change in ALSFRS, but also failed in four of its five secondary endpoints. Cytokinetics, Inc. (NASDAQ:CYTK) shares moved up 1.79% in last trading session and was closed at $4.54 while trading in range of $4.31 – $4.71 – Cytokinetics, Inc. (NASDAQ:CYTK) year to date (YTD) performance is -30.15%.
Incyte Corporation (NASDAQ:INCY) EVP James M. Daly sold 30,555 shares of Incyte stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $47.71, for a total transaction of $1,457,779.05. The transaction was disclosed in a document filed with the SEC. Incyte Corporation (NASDAQ:INCY) weekly performance is -1.44%. On last trading day company shares ended up $48.61. Incyte Corporation (NASDAQ:INCY) distance from 50-day simple moving average (SMA50) is -14.50%. Analysts mean target price for the company is $72.08.
Leave a Reply